Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Toxicology
Erschienen in: Cardiovascular Toxicology 9/2022

25.07.2022

Cardiac Remodelling Following Cancer Therapy: A Review

verfasst von: Tan Panpan, Du Yuchen, Shi Xianyong, Liu Meng, He Ruijuan, Dong Ranran, Zhang Pengyan, Li Mingxi, Xie Rongrong

Erschienen in: Cardiovascular Toxicology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Cardiac remodelling is characterized by abnormal changes in the function and morphological properties such as diameter, mass, normal diameter of cavities, heart shape, fibrosis, thickening of vessels and heart layers, cardiomyopathy, infiltration of inflammatory cells, and some others. These damages are associated with damage to systolic and diastolic abnormalities, damage to ventricular function, and vascular remodelling, which may lead to heart failure and death. Exposure of the heart to radiation or anti-cancer drugs including chemotherapy drugs such as doxorubicin, receptor tyrosine kinase inhibitors (RTKIs) such as imatinib, and immune checkpoint inhibitors (ICIs) can induce several abnormal changes in the heart structure and function through the induction of inflammation and fibrosis, vascular remodelling, hypertrophy, and some others. This review aims to explain the basic mechanisms behind cardiac remodelling following cancer therapy by different anti-cancer modalities.
Literatur
1.
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., et al. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer, 149(4), 778–789.CrossRef
2.
Liu, Y.-Q., Wang, X.-L., He, D.-H., & Cheng, Y.-X. (2021). Protection against chemotherapy-and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals. Phytomedicine, 80, 153402.PubMedCrossRef
3.
Minami, M., Matsumoto, S., & Horiuchi, H. (2010). Cardiovascular side-effects of modern cancer therapy. Circulation Journal, 2010, 1008100855.
4.
Perez, I. E., Taveras Alam, S., Hernandez, G. A., & Sancassani, R. (2019). Cancer therapy-related cardiac dysfunction: An overview for the clinician. Clinical Medicine Insights: Cardiology, 13, 1179546819866445.PubMedPubMedCentral
5.
Chen, D.-Y., Huang, W.-K., Wu, V.C.-C., Chang, W.-C., Chen, J.-S., Chuang, C.-K., et al. (2020). Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. Journal of the Formosan Medical Association., 119(10), 1461–75.PubMedCrossRef
6.
Zagar, T. M., Cardinale, D. M., & Marks, L. B. (2016). Breast cancer therapy-associated cardiovascular disease. Nature Reviews Clinical Oncology., 13(3), 172–184.PubMedCrossRef
7.
Boopathi, E., & Thangavel, C. (2021). Dark side of cancer therapy: Cancer Treatment-induced cardiopulmonary inflammation, fibrosis, and immune modulation. International Journal of Molecular Sciences, 22(18), 10126.PubMedPubMedCentralCrossRef
8.
Du, X. L., Xia, R., Liu, C. C., Cormier, J. N., Xing, Y., Hardy, D., et al. (2009). Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer, 115(22), 5296–5308.PubMedCrossRef
9.
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., et al. (2010). Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology, 55(3), 213–220.PubMedCrossRef
10.
Grover, S. P., Hisada, Y. M., Kasthuri, R. S., Reeves, B. N., & Mackman, N. (2021). Cancer therapy-associated thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 41(4), 1291–1305.PubMedPubMedCentralCrossRef
11.
Galvano, A., Guarini, A., Iacono, F., Castiglia, M., Rizzo, S., Tarantini, L., et al. (2019). An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. Expert Opinion on Drug Safety., 18(6), 485–496.PubMedCrossRef
12.
13.
Hochman, J. S., & Bulkley, B. H. (1982). Expansion of acute myocardial infarction: An experimental study. Circulation, 65(7), 1446–1450.PubMedCrossRef
14.
15.
16.
17.
Lu, M., Qin, X., Yao, J., Yang, Y., Zhao, M., & Sun, L. (2020). Th17/Treg imbalance modulates rat myocardial fibrosis and heart failure by regulating LOX expression. Acta Physiologica, 230(3), e13537.PubMedCrossRef
18.
Shao, P.-P., Liu, C.-J., Xu, Q., Zhang, B., Li, S.-H., Wu, Y., et al. (2018). Eplerenone reverses cardiac fibrosis via the suppression of tregs by inhibition of Kv1. 3 channel. Frontiers in Physiology, 9, 899.PubMedPubMedCentralCrossRef
19.
Fung, T. H., Yang, K. Y., & Lui, K. O. (2020). An emerging role of regulatory T-cells in cardiovascular repair and regeneration. Theranostics, 10(20), 8924.PubMedPubMedCentralCrossRef
20.
21.
Xiao, H., Li, H., Wang, J.-J., Zhang, J.-S., Shen, J., An, X.-B., et al. (2018). IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult. European Heart Journal, 39(1), 60–69.PubMedCrossRef
22.
23.
Hori, M., & Nishida, K. (2009). Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovascular Research, 81(3), 457–464.PubMedCrossRef
24.
Briasoulis, A., Androulakis, E., Christophides, T., & Tousoulis, D. (2016). The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Failure Reviews, 21(2), 169–176.PubMedCrossRef
25.
Grover, S., Lou, P., Bradbrook, C., Cheong, K., Kotasek, D., Leong, D., et al. (2015). Early and late changes in markers of aortic stiffness with breast cancer therapy. Internal Medicine Journal, 45(2), 140–147.PubMedCrossRef
26.
Raghunathan, D., Khilji, M. I., Hassan, S. A., & Yusuf, S. W. (2017). Radiation-induced cardiovascular disease. Current Atherosclerosis Reports, 19(5), 22.PubMedCrossRef
27.
Yusuf, S. W., Venkatesulu, B. P., Mahadevan, L. S., & Krishnan, S. (2017). Radiation-induced cardiovascular disease: A clinical perspective. Frontiers in Cardiovascular Medicine., 4, 66.PubMedPubMedCentralCrossRef
28.
Oun, R., & Rowan, E. (2017). Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node? European Journal of Pharmacology, 811, 125–128.PubMedCrossRef
29.
Patanè, S. (2014). Cardiotoxicity: Cisplatin and long-term cancer survivors. International Journal of Cardiology., 175(1), 201–202.PubMedCrossRef
30.
31.
32.
Mizia-Stec, K., Gościńska, A., Mizia, M., Haberka, M., Chmiel, A., Poborski, W., et al. (2013). Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiologia Polska, 71(7), 681–690.PubMedCrossRef
33.
Lupón, J., Gavidia-Bovadilla, G., Ferrer, E., de Antonio, M., Perera-Lluna, A., López-Ayerbe, J., et al. (2018). Dynamic trajectories of left ventricular ejection fraction in heart failure. Journal of the American College of Cardiology., 72(6), 591–601.PubMedCrossRef
34.
Kumar, S., Marfatia, R., Tannenbaum, S., Yang, C., & Avelar, E. (2012). Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. Texas Heart Institute Journal., 39(3), 424.PubMedPubMedCentral
35.
Trapani, D., Zagami, P., Nicolò, E., Pravettoni, G., & Curigliano, G. (2020). Management of cardiac toxicity induced by chemotherapy. Journal of Clinical Medicine., 9(9), 2885.PubMedCentralCrossRef
36.
Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., et al. (2019). Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research., 115(5), 854–868.PubMedPubMedCentralCrossRef
37.
Wu, Q.-Q., Xiao, Y., Yuan, Y., Ma, Z.-G., Liao, H.-H., Liu, C., et al. (2017). Mechanisms contributing to cardiac remodelling. Clinical Science., 131(18), 2319–2345.PubMedCrossRef
38.
Mortezaee, K., & Najafi, M. (2021). Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives. Critical Reviews in Oncology/Hematology., 157, 103180.PubMedCrossRef
39.
40.
41.
Ranpura, V., Hapani, S., Chuang, J., & Wu, S. (2010). Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncologica, 49(3), 287–297.PubMedCrossRef
42.
Economopoulou, P., Kotsakis, A., Kapiris, I., & Kentepozidis, N. (2015). Cancer therapy and cardiovascular risk: Focus on bevacizumab. Cancer Management and Research, 7, 133.PubMedPubMedCentralCrossRef
43.
Ghatalia, P., Morgan, C. J., Je, Y., Nguyen, P. L., Trinh, Q.-D., Choueiri, T. K., et al. (2015). Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 94(2), 228–237.PubMedCrossRef
44.
Khakoo, A. Y., Kassiotis, C. M., Tannir, N., Plana, J. C., Halushka, M., Bickford, C., et al. (2008). Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer: Interdisciplinary International Journal of the American Cancer Society., 112(11), 2500–2508.CrossRef
45.
Pentassuglia, L., Graf, M., Lane, H., Kuramochi, Y., Cote, G., Timolati, F., et al. (2009). Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Experimental Cell Research., 315(7), 1302–1312.PubMedPubMedCentralCrossRef
46.
47.
Harel, S., Mayaki, D., Sanchez, V., & Hussain, S. N. (2017). NOX2, NOX4, and mitochondrial-derived reactive oxygen species contribute to angiopoietin-1 signaling and angiogenic responses in endothelial cells. Vascular Pharmacology, 92, 22–32.PubMedCrossRef
48.
Navarro-Yepes, J., Burns, M., Anandhan, A., Khalimonchuk, O., Del Razo, L. M., Quintanilla-Vega, B., et al. (2014). Oxidative stress, redox signaling, and autophagy: Cell death versus survival. Antioxidants & Redox Signaling., 21(1), 66–85.CrossRef
49.
50.
51.
Palaskas, N., Patel, A., & Yusuf, S. W. (2019). Radiation and cardiovascular disease. Annals of Translational Medicine S371.
52.
Wang, B., Wang, H., Zhang, M., Ji, R., Wei, J., Xin, Y., et al. (2020). Radiation-induced myocardial fibrosis: Mechanisms underlying its pathogenesis and therapeutic strategies. Journal of Cellular and Molecular Medicine, 24(14), 7717–7729.PubMedPubMedCentralCrossRef
53.
Arola, O. J., Saraste, A., Pulkki, K., Kallajoki, M., Parvinen, M., & Voipio-Pulkki, L.-M. (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Research, 60(7), 1789–1792.PubMed
54.
Dhingra, R., Margulets, V., Chowdhury, S. R., Thliveris, J., Jassal, D., Fernyhough, P., et al. (2014). Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proceedings of the National Academy of Sciences., 111(51), E5537–E5544.CrossRef
55.
56.
57.
Farhood, B., Ashrafizadeh, M., Hoseini-Ghahfarokhi, M., Afrashi, S., Musa, A. E., & Najafi, M. (2020). Targeting of cellular redox metabolism for mitigation of radiation injury. Life Sciences., 250, 117570.PubMedCrossRef
58.
Wijerathne, H., Langston, J., Yang, Q., Sun, S., Miyamoto, C., Kilpatrick, L. E., et al. (2021). Mechanisms of radiation-induced endothelium damage: Emerging models and technologies. Radiotherapy and Oncology., 158, 21–32.PubMedPubMedCentralCrossRef
59.
60.
61.
Tada, Y., & Suzuki, J.-I. (2016). Oxidative stress and myocarditis. Current Pharmaceutical Design., 22(4), 450–71.PubMedCrossRef
62.
Bagchi, A. K., Malik, A., Akolkar, G., Jassal, D. S., & Singal, P. K. (2021). Endoplasmic reticulum stress promotes iNOS/NO and influences inflammation in the development of doxorubicin-induced cardiomyopathy. Antioxidants., 10(12), 1897.PubMedPubMedCentralCrossRef
63.
64.
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., et al. (2018). Myocarditis in patients treated with immune checkpoint inhibitors. Journal of the American College of Cardiology., 71(16), 1755–1764.PubMedPubMedCentralCrossRef
65.
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., et al. (2016). Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine., 375(18), 1749–1755.PubMedCrossRef
66.
Ji, C., Roy, M. D., Golas, J., Vitsky, A., Ram, S., Kumpf, S. W., et al. (2019). Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clinical Cancer Research., 25(15), 4735–4748.PubMedCrossRef
67.
Berner, A., Sharma, A., Agarwal, S., Al-Sam, S., & Nathan, P. (2018). Fatal autoimmune myocarditis with anti–PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer. European Journal of Cancer., 101, 287–290.PubMedCrossRef
68.
Burke, M. J., Walmsley, R., Munsey, T. S., & Smith, A. J. (2019). Receptor tyrosine kinase inhibitors cause dysfunction in adult rat cardiac fibroblasts in vitro. Toxicology in Vitro., 58, 178–186.PubMedCrossRef
69.
Rocca, C., De Francesco, E. M., Pasqua, T., Granieri, M. C., De Bartolo, A., Gallo Cantafio, M. E., et al. (2022). Mitochondrial determinants of anti-cancer drug-induced cardiotoxicity. Biomedicines., 10(3), 520.PubMedPubMedCentralCrossRef
70.
Truell, J. S., Fishbein, M. C., & Figlin, R. (2005). Myocarditis temporally related to the use of gefitinib (Iressa). Archives of Pathology & Laboratory Medicine., 129(8), 1044–1046.CrossRef
71.
72.
73.
Najafi, M., Motevaseli, E., Geraily, G., Norouzi, F., Heidari, M., & Rezapoor, S. (2017). The melatonin immunomodulatory actions in radiotherapy. Biophysical Reviews, 9(2), 139–148.PubMedPubMedCentralCrossRef
74.
75.
76.
77.
78.
79.
80.
81.
Yang, C.-M., Lee, I.-T., Hsu, R.-C., Chi, P.-L., & Hsiao, L.-D. (2013). NADPH oxidase/ROS-dependent PYK2 activation is involved in TNF-α-induced matrix metalloproteinase-9 expression in rat heart-derived H9c2 cells. Toxicology and Applied Pharmacology, 272(2), 431–442.PubMedCrossRef
82.
Mann, D. L., & Spinale, F. G. (1998). Activation of matrix metalloproteinases in the failing human heart: Breaking the tie that binds. Circulation, 98(17), 1699–1702.PubMedCrossRef
83.
Kizaki, K., Ito, R., Okada, M., Yoshioka, K., Uchide, T., Temma, K., et al. (2006). Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacological Research., 53(4), 341–346.PubMedCrossRef
84.
85.
Slezak, J., Kura, B., Babal, P., Barancik, M., Ferko, M., Frimmel, K., et al. (2017). Potential markers and metabolic processes involved in the mechanism of radiation-induced heart injury. Canadian Journal of Physiology and Pharmacology., 95(10), 1190–1203.PubMedCrossRef
86.
Bai, P., Mabley, J. G., Liaudet, L., Virág, L., Szabó, C., & Pacher, P. (2004). Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncology Reports, 11(2), 505–508.PubMed
87.
O’Hanlon, R., Grasso, A., Roughton, M., Moon, J. C., Clark, S., Wage, R., et al. (2010). Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. Journal of the American College of Cardiology., 56(11), 867–874.PubMedCrossRef
88.
89.
90.
de Groot, C., Beukema, J. C., Langendijk, J. A., van der Laan, H. P., van Luijk, P., van Melle, J. P., et al. (2021). Radiation-induced myocardial fibrosis in long-term esophageal cancer survivors. International Journal of Radiation Oncology Biology Physics, 110(4), 1013–1021.PubMedCrossRef
91.
92.
Tandri, H., Saranathan, M., Rodriguez, E. R., Martinez, C., Bomma, C., Nasir, K., et al. (2005). Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. Journal of the American College of Cardiology., 45(1), 98–103.PubMedCrossRef
93.
94.
Zhou, Z., Xu, L., Wang, R., Varga-Szemes, A., Durden, J. A., Joseph Schoepf, U., et al. (2019). Quantification of doxorubicin-induced interstitial myocardial fibrosis in a beagle model using equilibrium contrast-enhanced computed tomography: A comparative study with cardiac magnetic resonance T1-mapping. International Journal of Cardiology., 281, 150–155. https://​doi.​org/​10.​1016/​j.​ijcard.​2019.​01.​021CrossRefPubMed
95.
Zhou, Z., Wang, R., Wang, H., Liu, Y., Lu, D., Sun, Z., et al. (2021). Myocardial extracellular volume fraction quantification in an animal model of the doxorubicin-induced myocardial fibrosis: A synthetic hematocrit method using 3T cardiac magnetic resonance. Quantitative Imaging in Medicine and Surgery., 11(2), 510–520. https://​doi.​org/​10.​21037/​qims-20-501CrossRefPubMedPubMedCentral
96.
De Angelis, A., Urbanek, K., Cappetta, D., Piegari, E., Ciuffreda, L. P., Rivellino, A., et al. (2016). Doxorubicin cardiotoxicity and target cells: A broader perspective. Cardio-Oncology., 2(1), 1–8.CrossRef
97.
Piegari, E., De Angelis, A., Cappetta, D., Russo, R., Esposito, G., Costantino, S., et al. (2013). Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Research in Cardiology., 108(2), 1–18.CrossRef
98.
99.
100.
Farhood, B., Hoseini-Ghahfarokhi, M., Motevaseli, E., Mirtavoos-Mahyari, H., Musa, A. E., & Najafi, M. (2020). TGF-β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury. Pharmacological Research., 155, 104745.PubMedCrossRef
101.
Amini, P., Rezapoor, S., Shabeeb, D., Musa, A. E., Najafi, M., & Motevaseli, E. (2018). Evaluating the protective effect of a combination of curcumin and selenium-L-methionine on radiation induced dual oxidase upregulation. Pharmaceutical Sciences., 24(4), 340–345.CrossRef
102.
Lin, F., Wang, N., & Zhang, T. C. (2012). The role of endothelial–mesenchymal transition in development and pathological process. IUBMB Life, 64(9), 717–723.PubMedCrossRef
103.
Song, S., Zhang, R., Cao, W., Fang, G., Yu, Y., Wan, Y., et al. (2019). Foxm1 is a critical driver of TGF-β-induced EndMT in endothelial cells through Smad2/3 and binds to the Snail promoter. Journal of Cellular Physiology., 234(6), 9052–9064.PubMedCrossRef
104.
Choi, K. J., Nam, J.-K., Kim, J.-H., Choi, S.-H., & Lee, Y.-J. (2020). Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage. Experimental & Molecular Medicine., 52(5), 781–792.CrossRef
105.
106.
107.
Tsai, T.-H., Lin, C.-J., Hang, C.-L., & Chen, W.-Y. (2019). Calcitriol attenuates doxorubicin-induced cardiac dysfunction and inhibits endothelial-to-mesenchymal transition in mice. Cells, 8(8), 865.PubMedCentralCrossRef
108.
Nie, L., Liu, M., Chen, J., Wu, Q., Li, Y., Yi, J., et al. (2021). Hydrogen sulfide ameliorates doxorubicin-induced myocardial fibrosis in rats via the PI3K/AKT/mTOR pathway. Molecular Medicine Reports, 23(4), 1–11.CrossRef
109.
110.
Arafa, M. H., Mohammad, N. S., Atteia, H. H., & Abd-Elaziz, H. R. (2014). Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. Journal of Physiology and Biochemistry, 70(3), 701–711.PubMedCrossRef
111.
Saleh, M. A., Antar, S. A., Hazem, R. M., & El-Azab, M. F. (2020). Pirfenidone and vitamin D ameliorate cardiac fibrosis induced by doxorubicin in ehrlich ascites carcinoma bearing mice: Modulation of monocyte chemoattractant protein-1 and Jun N-terminal kinase-1 pathways. Pharmaceuticals, 13(11), 348.PubMedCentralCrossRef
112.
Sahna, E., Parlakpinar, H., Ozer, M. K., Ozturk, F., Ozugurlu, F., & Acet, A. (2003). Melatonin protects against myocardial doxorubicin toxicity in rats: Role of physiological concentrations. Journal of Pineal Research, 35(4), 257–261.PubMedCrossRef
113.
Shaty, M. H., Arif, I. S., Al-Ezzi, M. I., & Hanna, D. B. (2018). Metformin attenuate fibrosis in both acute and chronic doxorubicin cardiotoxicity in rabbits. Journal of Pharmaceutical Sciences and Research, 10(6), 1559–1565.
114.
Katamura, M., Iwai-Kanai, E., Nakaoka, M., Okawa, Y., Ariyoshi, M., Mita, Y., et al. (2014). Curcumin attenuates doxorubicin-induced cardiotoxicity by inducing autophagy via the regulation of JNK phosphorylation. Journal of Clinical and Experimental Cardiology, 5(09), 1–8.CrossRef
115.
116.
Vatanen, A., Sarkola, T., Ojala, T. H., Turanlahti, M., Jahnukainen, T., Saarinen-Pihkala, U. M., et al. (2015). Radiotherapy-related arterial intima thickening and plaque formation in childhood cancer survivors detected with very-high resolution ultrasound during young adulthood. Pediatric Blood & Cancer, 62(11), 2000–2006.CrossRef
117.
Huang, T. L., Hsu, H. C., Chen, H. C., Lin, H. C., Chien, C. Y., Fang, F. M., et al. (2013). Long-term effects on carotid intima-media thickness after radiotherapy in patients with nasopharyngeal carcinoma. Radiation Oncology., 8(1), 1–6.CrossRef
118.
119.
Berliner, S., Rahima, M., Sidi, Y., Teplitsky, Y., Zohar, Y., Nussbaum, B., et al. (1990). Acute coronary events following cisplatin-based chemotherapy. Cancer Investigation, 8(6), 583–586.PubMedCrossRef
120.
121.
Vogelzang, N. J., Frenning, D. H., & Kennedy, B. J. (1980). Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treatment Reports, 64(10–11), 1159–1160.PubMed
122.
123.
124.
Haubner, F., Ohmann, E., Pohl, F., Prantl, L., Strutz, J., & Gassner, H. G. (2013). Effects of radiation on the expression of adhesion molecules and cytokines in a static model of human dermal microvascular endothelial cells. Clinical Hemorheology and Microcirculation, 54(4), 371–379. https://​doi.​org/​10.​3233/​ch-2012-1626CrossRefPubMed
125.
126.
Hoving, S., Heeneman, S., Gijbels, M. J., te Poele, J. A., Russell, N. S., Daemen, M. J., et al. (2008). Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(-/-) mice. International Journal of Radiation Oncology Biology Physics, 71(3), 848–857. https://​doi.​org/​10.​1016/​j.​ijrobp.​2008.​02.​031CrossRefPubMed
127.
128.
129.
130.
131.
Carta, S., Castellani, P., Delfino, L., Tassi, S., Vene, R., & Rubartelli, A. (2009). DAMPs and inflammatory processes: The role of redox in the different outcomes. Journal of Leukocyte Biology, 86(3), 549–555.PubMedCrossRef
132.
133.
134.
135.
Sato, A., Yoshihisa, A., Miyata-Tatsumi, M., Oikawa, M., Kobayashi, A., Ishida, T., et al. (2019). Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer. Molecular and Clinical Oncology, 10(1), 37–42.PubMed
136.
Cella, L., Oh, J. H., Deasy, J. O., Palma, G., Liuzzi, R., D’avino, V., et al. (2015). Predicting radiation-induced valvular heart damage. Acta Oncologica., 54(10), 1796–1804.PubMedCrossRef
137.
Bijl, J. M., Roos, M. M., van Leeuwen-Segarceanu, E. M., Vos, J. M., Bos, W.-J.W., Biesma, D. H., et al. (2016). Assessment of valvular disorders in survivors of Hodgkin’s lymphoma treated by mediastinal radiotherapy±chemotherapy. The American Journal of Cardiology., 117(4), 691–696.PubMedCrossRef
138.
Gujral, D. M., Lloyd, G., & Bhattacharyya, S. (2016). Radiation-induced valvular heart disease. Heart, 102(4), 269–276.PubMedCrossRef
139.
Nadlonek, N. A., Weyant, M. J., Jessica, A. Y., Cleveland, J. C., Jr., Reece, T. B., Meng, X., et al. (2012). Radiation induces osteogenesis in human aortic valve interstitial cells. The Journal of Thoracic and Cardiovascular Surgery., 144(6), 1466–1470.PubMedPubMedCentralCrossRef
140.
141.
Barrick, C. J., Roberts, R. B., Rojas, M., Rajamannan, N. M., Suitt, C. B., O’Brien, K. D., et al. (2009). Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. American Journal of Physiology-Heart and Circulatory Physiology., 297(1), H65–H75.PubMedPubMedCentralCrossRef
142.
143.
144.
145.
146.
147.
Grela-Wojewoda, A., Niemiec, J., Sas-Korczyńska, B., Zemełka, T., Puskulluoglu, M., & Wysocki, W. M. et al. (2022). Adjuvant combined therapy with trastuzumab in patients with HER2-positive breast cancer and cardiac alterations: Implications for optimal cardio-oncology care. Polish Archives of Internal Medicine.
148.
Ewer, S. M., & Ewer, M. S. (2008). Cardiotoxicity profile of trastuzumab. Drug Safety, 31(6), 459–467.PubMedCrossRef
149.
150.
Saiki, H., Moulay, G., Guenzel, A. J., Liu, W., Decklever, T. D., Classic, K. L., et al. (2017). Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. American Journal of Physiology-Heart and Circulatory Physiology., 313(2), H392–H407.PubMedPubMedCentralCrossRef
151.
152.
153.
Luk, A., Ahn, E., Soor, G. S., & Butany, J. (2009). Dilated cardiomyopathy: A review. Journal of Clinical Pathology., 62(3), 219–225.PubMedCrossRef
154.
155.
156.
Maisel, W. H., & Stevenson, L. W. (2003). Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. The American Journal of Cardiology., 91(6), 2–8.CrossRef
157.
Stevenson, W. G., & Stevenson, L. W. (1999). Atrial fibrillation in heart failure (pp. 910–911). Waltham: Mass Medical Soc.
158.
O’Neal, W. T., Lakoski, S. G., Qureshi, W., Judd, S. E., Howard, G., Howard, V. J., et al. (2015). Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). The American Journal of Cardiology., 115(8), 1090–1094.PubMedPubMedCentralCrossRef
159.
160.
161.
162.
163.
164.
Benjanuwattra, J., Siri-Angkul, N., Chattipakorn, S. C., & Chattipakorn, N. (2020). Doxorubicin and its proarrhythmic effects: A comprehensive review of the evidence from experimental and clinical studies. Pharmacological Research., 151, 104542.PubMedCrossRef
165.
166.
Zhao, L. (2019). Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction. Anatolian Journal of Cardiology., 22(5), 232.PubMedPubMedCentral
167.
Darling, H. (2015). Cisplatin induced bradycardia. International Journal of Cardiology., 182, 304–306.PubMedCrossRef
Metadaten
Titel
Cardiac Remodelling Following Cancer Therapy: A Review
verfasst von
Tan Panpan
Du Yuchen
Shi Xianyong
Liu Meng
He Ruijuan
Dong Ranran
Zhang Pengyan
Li Mingxi
Xie Rongrong
Publikationsdatum
25.07.2022
Verlag
Springer US
Erschienen in
Cardiovascular Toxicology / Ausgabe 9/2022
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-022-09762-6

Weitere Artikel der Ausgabe 9/2022

Cardiovascular Toxicology 9/2022 Zur Ausgabe

OriginalPaper

LncRNA MALAT1 Regulates USP22 Expression Through EZH2-Mediated H3K27me3 Modification to Accentuate Sepsis-Induced Myocardial Dysfunction

OriginalPaper

QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with “Known Risk of Torsades de Pointes”

OriginalPaper

Development and Validation of a Diagnostic Nomogram to Predict the Anthracycline-Induced Early Cardiotoxicity in Children with Hematological Tumors

OriginalPaper

An Improved Monkey Model of Myocardial Ischemic Infarction for Cardiovascular Drug Development

OriginalPaper

Maternal Ethanol Exposure-Induced Cardiac Fibrosis is Associated with Changes in TGF-β and SIRT1/FOXO3a Signaling in Male Rat Offspring: A Three-Month Follow-up Study

OriginalPaper

Salvianolic Acid B Alleviates Myocardial Ischemia Injury by Suppressing NLRP3 Inflammasome Activation via SIRT1-AMPK-PGC-1α Signaling Pathway